Biopharmaceutical Firm DICE Therapeutics Prices Upsized US$204 Million IPO

Biopharmaceutical company DICE Therapeutics, Inc. (Nasdaq: DICE) started publicly trading on the Nasdaq Global Market yesterday under the symbol “DICE”. The firm’s initial public offering is looking to raise US$204.0 million and is expected to close on September 17, 2021.

The offering will be conducted through the issuance of 12.0 million common shares selling at US$17.00 per share. This is an adjustment from the company’s original plan to issue 10.0 million shares with share price expectations between US$15.00 and US$17.00.

The company granted the underwriters a 30-day over-allotment option to purchase additional 1.8 million common shares at the same IPO price, potentially bringing proceeds up to US$82.8 million. BofA Securities, SVB Leerink, and Evercore ISI are all acting as joint bookrunners for the said offering.

Silver47 Exploration Inc. — sponsored Sponsored · Silver47 Exploration Inc.

The California-based biotech firm is in the business of developing immunotherapies for patients with chronic diseases. Currently, the firm’s lead therapeutic candidate S011806 is an oral antagonist targeting a pro-inflammatory signaling molecule connected with a variety of immunology indications. The orally-available candidate is expected to enter its phase 1 trial in the second half of 2021.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Majestic Hits 4.24 g/t Gold Over 48.8 Metres at Saval as Jerritt Canyon Restart Advances

First Majestic Lifts Q3 Revenue 38% to US$394.1 Million on Higher Silver Prices

Related News

Fintech Firm Blend Labs Seeks US$360 Million In IPO

Blend Labs Inc. announced this morning the launch of its initial public offering on the...

Tuesday, July 6, 2021, 11:20:00 AM

Restaurant Operator Yoshiharu Prices Upsized US$11.8 Million IPO

Restaurant operator Yoshiharu Global Co. (Nasdaq: YOSH) started trading on the Nasdaq Capital Market on...

Friday, September 9, 2022, 02:22:00 PM

Edtech Firm PowerSchool Prices Its US$711 Million IPO

Software firm for K-12 education PowerSchool Holdings, Inc., (NYSE: PWSC) began trading on the New...

Thursday, July 29, 2021, 10:12:00 AM

Industrials SPAC Kensington Capital Acquisition V Eyes US$240 Million IPO

Special purpose acquisition company Kensington Capital Acquisition Corp. V (NYSE: KCGI.U) started trading its securities...

Friday, August 13, 2021, 10:03:00 AM

Robinhood Covertly Files for US IPO

Fresh from its discomfiting Congressional hearing and onslaught of scrutiny from retail trading fanatics over...

Wednesday, March 24, 2021, 09:42:00 AM